Literature DB >> 2466100

Neutralizing activity of antibodies against the major herpes simplex virus type 1 glycoproteins.

B R Eing1, J E Kühn, R W Braun.   

Abstract

The specificity and neutralizing activity of antibodies against the major herpes simplex virus type 1 (HSV-1) glycoproteins were tested in serum samples of patients with a history of HSV-1 infection. By preabsorption of sera to preparations of native and denatured HSV-1 proteins, followed by immunoblotting and microneutralization, it was shown that the majority of neutralizing antibodies are directed against denaturation-sensitive epitopes. Furthermore, preabsorption of sera to proteins of viral ts and deletion mutants revealed that antibodies specific for gB, gC, and gE had a low neutralizing activity. These results suggest a major role of anti-gD in neutralization of viral infectivity. In addition, it was shown that antibodies directed against the gB monomer were distinct from antibodies against the gB homodimers. The latter, however, did not reveal any measurable neutralizing activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2466100     DOI: 10.1002/jmv.1890270113

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

1.  Reactivity of human sera with overlapping synthetic peptides of herpes simplex virus type 1 glycoprotein D.

Authors:  H J Geerligs; M Feijlbrief; M Bolk; C A Bos; J W Drijfhout; G W Welling; S Welling-Wester
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

2.  Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans.

Authors:  Tina M Cairns; Zhen-Yu Huang; J Charles Whitbeck; Manuel Ponce de Leon; Huan Lou; Anna Wald; Claude Krummenacher; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

3.  Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific.

Authors:  Tina M Cairns; Zhen-Yu Huang; John R Gallagher; Yixin Lin; Huan Lou; J Charles Whitbeck; Anna Wald; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

4.  Identification of herpes simplex virus type 1 glycoproteins interacting with the cell surface.

Authors:  J E Kühn; M D Kramer; W Willenbacher; U Wieland; E U Lorentzen; R W Braun
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

5.  Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.

Authors:  Michael T Hensel; Jason D Marshall; Michael R Dorwart; Darren S Heeke; Eileen Rao; Padmaja Tummala; Li Yu; Gary H Cohen; Roselyn J Eisenberg; Derek D Sloan
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

6.  HSV-1 gB and VZV gp-II crossreactive antibodies in human sera.

Authors:  J E Kühn; K Klaffke; K Munk; R W Braun
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

7.  Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries.

Authors:  P P Sanna; R A Williamson; A De Logu; F E Bloom; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

8.  Relatedness of glycoproteins expressed on the surface of simian herpes-virus virions and infected cells to specific HSV glycoproteins.

Authors:  R Eberle; D Black; J K Hilliard
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

9.  Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial.

Authors:  Geert Leroux-Roels; Frédéric Clément; Pierre Vandepapelière; Marc Fourneau; Thomas C Heineman; Gary Dubin
Journal:  Hum Vaccin Immunother       Date:  2013-02-22       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.